Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from MaxCyte ( (MXCT) ).
MaxCyte, Inc. announced plans to release its financial results for the fourth quarter and full year of 2024 on March 11, 2025, followed by a conference call to discuss the outcomes. The company will also participate in the 45th Annual TD Cowen Healthcare Conference with a fireside chat on March 3, 2025. This announcement demonstrates MaxCyte’s commitment to transparency and stakeholder engagement, potentially strengthening its position in the cell engineering sector.
More about MaxCyte
MaxCyte, Inc., is a prominent company in the cell engineering industry, providing platform technologies that facilitate the advancement of cell therapeutics. Their ExPERT™ platform, based on Flow Electroporation® technology, supports the cell therapy market across various stages, from discovery to commercialization. The company offers a range of instruments, processing assemblies, and software protocols, backed by a strong intellectual property portfolio, aimed at transforming human health.
YTD Price Performance: 9.57%
Average Trading Volume: 63,165
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £392.2M
For a thorough assessment of MXCT stock, go to TipRanks’ Stock Analysis page.
